Lineage Cell Therapeutics, Inc. (LCTX)

NYSEAMERICAN: LCTX · IEX Real-Time Price · USD
1.57 -0.08 (-4.85%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap264.64M
Revenue (ttm)3.53M
Net Income (ttm)-12.00M
Shares Out168.56M
EPS (ttm)-0.08
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,136,870
Open1.65
Previous Close1.65
Day's Range1.57 - 1.67
52-Week Range1.55 - 3.13
Beta1.71
AnalystsBuy
Price Target6.40 (+307.6%)
Earnings Daten/a

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute sp...

IndustryBiotechnology
Founded1990
CEOBrian Culley
Employees49
Stock ExchangeNYSEAMERICAN
Ticker SymbolLCTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is 6.40, which is an increase of 307.64% from the latest price.

Price Target
$6.40
(307.64% upside)
Analyst Consensus: Buy

News

Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapi...

2 weeks ago - Business Wire

Why Lineage Cell Therapeutics Zoomed Higher Today

The biotech stands to reap hundreds of millions of dollars from a new collaboration with a top pharmaceutical player.

1 month ago - The Motley Fool

Hot Penny Stocks To Buy For Under $5 Right Now

Making a list of the best penny stocks to buy now? These 4 have turned heads in the stock market today.

Other symbols:AHIBDSI
1 month ago - PennyStocks

Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY) Genentech to develop and commercialize retina...

1 month ago - Benzinga

Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpR...

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, Cell Cure Neuroscie...

1 month ago - Business Wire

Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

1 month ago - Business Wire

OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

2 months ago - Business Wire

Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0.00% and 305.36%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

2 months ago - Business Wire

Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, ...

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

2 months ago - Business Wire

Analysts Estimate Lineage Cell (LCTX) to Report a Decline in Earnings: What to Look Out for

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Micha...

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

2 months ago - Business Wire

Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

3 months ago - Business Wire

Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christo...

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

3 months ago - Business Wire

Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

4 months ago - Business Wire

Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical ...

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

4 months ago - Business Wire

Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. ...

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

4 months ago - Business Wire

Lineage Announces Appointment of General Counsel

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

4 months ago - Business Wire

Lineage Cell (LCTX) Reports Q2 Loss, Misses Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0.00% and -51.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy P...

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

5 months ago - Business Wire

Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game?

Image by Rudy and Peter Skitterians from Pixabay   Age-related macular degeneration (AMD) is a disease originating in the retina, which may worsen over time, according to WebMD. It's said to be the lead...

Other symbols:AMD
5 months ago - Benzinga

Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

5 months ago - Business Wire

Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

5 months ago - Business Wire

OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With ...

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

6 months ago - Business Wire

OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Ri...

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

6 months ago - Business Wire